Related Experiment Video
Updated: May 25, 2025
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Challenges Related to Out-of-Pocket Costs in Heart Failure Management
Birju R Rao1, Larry A Allen2,3, Alexander T Sandhu4,5
1Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA (B.R.R., N.W.D.).
Insights
High out-of-pocket costs for heart failure treatment can lead to financial toxicity. Developing cost-effective treatment plans requires addressing patient costs, policy interventions, and shared decision-making strategies.
Area of Science:
- Health Economics
- Cardiology
- Health Policy
Background:
- High out-of-pocket costs for heart failure (HF) treatments, particularly guideline-directed medical therapy (GDMT) for HF with reduced ejection fraction, pose significant financial burdens.
- Comorbidities common in HF patients further increase treatment costs and financial toxicity.
- Current healthcare systems face challenges in estimating patient-specific costs and integrating cost considerations into treatment planning.
Purpose of the Study:
- To examine the challenges associated with high out-of-pocket costs in heart failure treatment.
- To explore strategies for mitigating financial toxicity while optimizing patient outcomes.
- To discuss the role of health policy and shared decision-making in managing treatment costs.
Main Methods:
- Review of current literature on heart failure treatment costs and financial toxicity.
- Analysis of factors contributing to out-of-pocket expenses for heart failure patients.
- Examination of existing and proposed health policy interventions and patient-level strategies.
Main Results:
- Out-of-pocket costs for heart failure patients are complex, influenced by insurance, pharmacy benefits, and multiple comorbidities.
- Mitigating financial toxicity requires multifaceted approaches, including health policy changes and patient-centered interventions.
- Integrating cost discussions into shared decision-making is crucial but lacks established best practices.
Conclusions:
- Addressing financial toxicity in heart failure is essential for improving treatment adherence and patient well-being.
- Policy solutions like the Inflation Reduction Act and value-based insurance design show promise for cost relief.
- Enhancing shared decision-making and patient engagement are vital for long-term management of heart failure costs.
Abstract:
High out-of-pocket costs and financial toxicity related to heart failure treatment are substantial concerns. Two of 4 pillars of guideline-directed medical therapy for heart failure with reduced ejection fraction, for example, carry high costs that may attenuate their uptake. Furthermore, heart failure rarely occurs in isolation. Many patients have other comorbidities that require treatment, further driving up patients' out-of-pocket costs. Developing treatment plans that improve mortality without subjecting patients to financial toxicity can be challenging for several reasons. First, patients with heart failure can accrue out-of-pocket costs from multiple domains and can depend on a variety of insurance and pharmacy-related factors that can make determining patient-specific out-of-pocket cost estimates complicated. Second, strategies to mitigate financial toxicity involve health policy-level interventions and patient-level interventions. These have their own unique sets of challenges. Third, integrating out-of-pocket costs into shared decision-making requires nuanced and challenging discussions about whether a therapy is worth the cost. Though shared decision-making has been advocated, there are little data on how to best conduct these discussions. Health policies like the Inflation Reduction Act of 2022 may provide relief to some patients, and efforts to improve transparency have the potential to be beneficial. Over the long term, policy solutions such as value-based insurance design and patient engagement solutions that emphasize enhancing shared decision-making have important potential to yield durable results.
Related Concept Videos
01:26Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
01:17Pathophysiology of Heart Failure
01:22Heart Failure Drugs: Diuretics
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:22Heart Failure Drugs: β-Blockers